PCM
LJPC

Prelude Capital Management’s La Jolla Pharmaceutical Company LJPC Stock Holding History

Prelude Capital Management’s Portfolio LJPC Stock Details LJPC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-5,000
Closed -$149K – 2168
2018
Q1 		$149K Buy
+5,000
New +$161K 0.01% 758

Other funds holding LJPC

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Prelude Capital Management's LJPC Position: Q4 2018 in Review

Prelude Capital Management sold out of La Jolla Pharmaceutical Company (LJPC) in Q4 2018, closing a stake of 4,500 shares — an estimated $91K sold.

Prelude Capital Management first reported a position in LJPC in Q4 2015 and held it in 6 quarters. The position peaked at $1.01M in Q1 2018. 83 funds tracked by Wall St. Rank hold LJPC as of Q4 2018.

  • Prelude Capital Management reported no remaining La Jolla Pharmaceutical Company position as of Q4 2018 after selling out during the quarter.
  • Prelude Capital Management sold 4,500 La Jolla Pharmaceutical Company shares in Q4 2018, an estimated $91K.
  • Prelude Capital Management first reported a position in La Jolla Pharmaceutical Company in Q4 2015 and held it in 6 quarters.
  • Prelude Capital Management's La Jolla Pharmaceutical Company position peaked at $1.01M in Q1 2018.
  • 83 funds tracked by Wall St. Rank held La Jolla Pharmaceutical Company as of Q4 2018.

Based on Prelude Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.